Placentas from healthy women living in a cutaneous leishmaniasis endemic region in Mexico harbor Leishmania mexicana parasites: Potential implications for pregnancy and neonatal outcomes Authors: Rodrigo X. Armijos, Brandon A. Berger, Alejandra González Ayala, Miriam A. Delgado-Hernandez, José Luis Acosta-Patiño, Esmelin Trinidad-Vázquez, Liliana Aline Fernández-Urrutia, Elizabeth Baz-Rojas, Javier Mancilla-Galindo, Candelaria Frías Selván, Juana Ortíz-Avalos, Eva Cristina Avalos-Ortiz, Frida Häberle, Miriam Torres-Vasquez, M. Margaret Weigel, Allison H. Bartlett, Yuriria Paredes, Miroslava Avila-García, Magdalena Aguirre García, Norma Galindo-Sevilla, Andrés F. Henao-Martínez, Susan Madison-Antenucci, Andrés F. Henao-Martínez, Susan Madison-Antenucci, Andrés F. Henao-Martínez, Susan Madison-Antenucci Published: 2026 ABSTRACT BackgroundWomen living in leishmaniasis-endemic zones are regularly exposed to the sandfly vector in their environments. While case series and laboratory evidence consistently suggest transplacental transmission of Leishmania parasites with deleterious maternal-fetal effects, this issue has received insufficient attention, particularly in areas where the predominant Leishmania species is mainly associated with cutaneous disease.Methodology/principal findingsWe conducted an exploratory cross-sectional study in a highly endemic zone of Tabasco, Mexico, enrolling 53 women with singleton term deliveries between April 2018 and April 2020. Placental PCR was positive in 18 (34%) participants. Buccal swabs were positive in 11 (21.2%) of 52 newborns. Immunofluorescence confirmed intracellular amastigotes within macrophages near the vascular endothelium of PCR-positive placentas, with no surrounding inflammatory infiltration. Sequencing revealed homology to Leishmania mexicana, L. amazonensis, or L. panamensis. Birthweight percentile was modestly lower in the PCR-positive group (predicted mean 53.8% vs. 56.5%, p = 0.76), while small for gestational age showed a non-significant trend toward higher prevalence among PCR-positive cases (prevalence ratio = 2.06, 95% CI: 0.32–13.39, p = 0.45).Conclusions/significanceSubclinical, dynamic transmission of Leishmania parasites typically associated with cutaneous disease was detected in this endemic zone. The presence of L. mexicana in human placentas was confirmed by immunofluorescence and sequencing, without an associated inflammatory response. These findings highlight the potential of CL-associated Leishmania species to reach the placenta and buccal mucosa of newborns, warranting further epidemiological investigation into the consequences of vertical transmission in regions with endemic CL. Introduction Leishmaniasis is a protozoal infection caused by Leishmania parasites and is traditionally classified into visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). VL is characterized by hepatosplenomegaly, fever, anemia, and weight loss, whereas CL manifests as granulomatous or ulcerative skin lesions. Globally, an estimated 900,000 to 1.6 million new cases occur each year [1]. Transmission occurs through the bite of infected sandflies, primarily Lutzomyia in the Americas and Phlebotomus in the Old World. In endemic regions, up to one in 50 sandflies may harbor Leishmania [2]. Laboratory studies suggest female sandflies have short adult lifespans, typically fewer than 20 days, though natural populations may live considerably longer [3]. Mature females require a blood meal during each oviposition cycle; with inter-bite intervals averaging approximately 6 days, they typically acquire parasites from only a small number of blood meals over their lifespan [3]. Although cutaneous lesions are recognized in humans and animals, they occur relatively infrequently, raising the question of potential subclinical infection [4]. Treatment of leishmaniasis, particularly during pregnancy, is challenging. The only compound with demonstrated efficacy and an acceptable safety profile in pregnant women with visceral leishmaniasis is liposomal amphotericin B [5]. Experience in pregnant women with cutaneous leishmaniasis is scarce, although liposomal amphotericin B has recently been used successfully [6]. Physical methods such as thermotherapy or cryotherapy may also be safe during pregnancy for cutaneous leishmaniasis, although their effects on the fetus remain unknown; immunotherapeutic and vaccine approaches remain experimental [7]. None is established for the prevention or treatment of subclinical or congenital infection, which underscores the importance of recognizing at-risk groups such as pregnant women living in endemic regions. The fact that Leishmania parasites have been detected in the blood of both symptomatic patients and asymptomatic individuals living in endemic areas of CL [8] suggests that CL infection is not limited to skin alone. Animal models provide additional evidence supporting this observation: Leishmania parasites may disseminate to distant tissues [9], including the placenta, as demonstrated in a murine model [10]. This finding challenges the traditional dichotomy in which VL is viewed as strictly systemic and CL as strictly cutaneous. The placenta presents a unique opportunity to investigate subclinical infection due to its high degree of vascularization and routine expulsion after delivery. It receives approximately 0.5 litres of blood per minute, meaning that the total blood volume of an adult circulates through it every ten minutes [11]. This extensive circulation enables continuous exchange of nutrients, immune cells, and potentially pathogens between the mother and fetus. During passage through the placenta, some parasites may cross the barrier, a phenomenon well described for malaria, Chagas’ disease, and toxoplasmosis, which has been linked to adverse maternal and infant outcomes including anemia, low birth weight, pre-eclampsia, restricted fetal growth, and infant mortality [12,13]. Given these parallels, it is plausible that Leishmania may also cross the placenta, leading to adverse pregnancy outcomes [14]. Evidence supporting vertical transmission of Leishmania has been described in VL, where both symptomatic and asymptomatic mothers have been shown to transmit the parasite to their offspring [5,15,16]. However, studies on the vertical transmission of CL-associated species remain scarce, although their findings are suggestive. In a Brazilian cohort of pregnant women with CL (n = 26), 10.5% experienced preterm birth and 10.5% had stillbirths, both associated with exuberant lesions [17]. Additionally, L. mexicana was identified as the cause of visceral leishmaniasis in a 6-month-old infant from Tabasco, the first visceral case reported in this region where cutaneous disease predominates, indicating that a species typically associated with cutaneous leishmaniasis can visceralize in early childhood [18]. Nevertheless, the prevalence of Leishmania infection (clinical or subclinical) among women of reproductive age, and the effects of locally endemic CL-associated strains such as L. mexicana on birth outcomes, remain largely unknown. Given that suboptimal fetal growth is six times more prevalent in developing regions [19], many of which overlap with leishmaniasis-endemic zones, it is important to determine whether any relationship exists between them. Diseases caused by protozoa (malaria, toxoplasmosis, Chagas disease, and visceral leishmaniasis) are well-documented causes of adverse fetal development, prompting public health efforts to enhance screening, diagnosis, and treatment [20,21]. In contrast, leishmaniasis, particularly CL-associated strains, has not received the same level of attention as a potential threat to perinatal health. No study has systematically investigated the presence of Leishmania in placental tissue from women in CL-endemic regions, alongside the buccal mucosa of their newborns, or its potential association with adverse perinatal outcomes. We conducted an exploratory cross-sectional study in a highly endemic zone of Tabasco, Mexico, with three specific aims: (1) to determine the frequency of placental infection by Leishmania sp. by PCR analysis, hypothesizing that subclinical infection by CL-associated species could be identified in the placentas of women living in endemic zones; (2) to ascertain the frequency of Leishmania sp. infection in the oral mucosa of newborns, hypothesizing that vertical transmission could occur either hematogenously or via parasite-harboring amniotic fluid reaching the buccal mucosa of the fetus; and (3) to explore the association of placental Leishmania infection with fetal growth, hypothesizing that infection would be associated with fetal growth restriction. Materials and methods Ethics statement The study protocol was approved by the Institutional Review Boards of the Instituto Nacional de Perinatología (#2017-3-116), the Secretaría de Salud de Tabasco (#INV/2133/PCI/1116), and Indiana University (#1905780741). All participants provided written informed consent during prenatal consultations. As the legal guardians of the neonates, mothers granted written consent for their newborn children’s participation, covering placental sampling, buccal swab, and urine collection performed at delivery. A red dot label was placed on clinical records after providing consent to identify study participants as placental donors at hospital arrival for delivery. All participants received standard-of-care prenatal and delivery care at no cost, as provided within the public health system, at a secondary or tertiary care hospital in the study area. PCR-positive results were not treated as clinical cases of leishmaniasis. The detection of parasite DNA is not equivalent to active clinical infection; furthermore, the drugs used to treat clinical leishmaniasis carry significant risks including hepatotoxicity and nephrotoxicity that outweigh likely benefits in the absence of clinical disease. Quarterly technical reports were submitted to health authorities in Tabasco to ensure follow-up monitoring of mothers and infants for potential CL lesions or clinical signs of vertical transmission. Study design and setting We conducted a cross-sectional exploratory study in Tabasco, Mexico, a State in the south-east of the country encompassing some of the highest CL-endemic zones in Mexico. Highly endemic zones, defined as areas with more than 200 cases per 10,000 inhabitants in the preceding five years, were selected for sampling. Study zones were selected on the basis of the availability of National Health Services (Secretaría de Salud) facilities and accessibility by road (Fig 1). Regional distribution of placental leishmaniasis (PCR-positive) cases and land use in Cunduacán and neighboring municipalities (Tabasco, Mexico, 2017–2019). (A) Geographic location of the study area within Mexico. (B) Spatial distribution of sampled localities by placental PCR status. Each circle represents a sampled locality centroid from the INEGI 2020 Geostatistical Framework, the smallest geographic unit reported in publicly available census data; circle size is proportional to the number of women aged 15–49 years per locality (INEGI Census 2020). Red circles indicate localities with at least one PCR-positive placental sample; cyan circles indicate localities where all samples were PCR-negative. Map data sources: Panel A (country and state outlines): Natural Earth 1:10m cultural vectors, public domain (https://www.naturalearthdata.com/downloads/10m-cultural-vectors/; licence: https://www.naturalearthdata.com/about/terms-of-use/). Panels A–B (municipal boundaries): INEGI Municipal Geostatistical Framework, 2020 (https://en.www.inegi.org.mx/app/biblioteca/ficha.html?upc=889463807469). Panel B (land use and vegetation): INEGI Land Use and Vegetation Series VII, 1:250,000, 2018 (https://en.www.inegi.org.mx/app/biblioteca/ficha.html?upc=889463842781). Water bodies in Panel B are shown as the inland-water areas of the same INEGI Land Use and Vegetation layer (Series VII). Panel B (road network): INEGI National Road Network, 2020 (https://en.www.inegi.org.mx/app/biblioteca/ficha.html?upc=702825292805). All INEGI datasets and shapefiles are published under Mexico’s open-data licence (https://en.www.inegi.org.mx/inegi/terminos.html). Three secondary-level regional hospitals located in Cárdenas, Comalcalco, and Paraíso, and two tertiary-level hospitals (Hospital de la Mujer and Hospital Rovirosa) where women with complicated pregnancies are referred, were invited to participate. Community health houses (casas de salud) managed by the Tabasco Health Services were used as recruitment centers for pregnant women beginning at their first prenatal visit. Participating women then delivered at the corresponding hospital facility. Participant recruitment. Women were eligible for inclusion if they: resided in a highly endemic CL zone, were in their first trimester of pregnancy, carried a singleton fetus, and received prenatal care at one of the participating Secretaría de Salud facilities. Women were excluded if they had multiple fetuses, a molar pregnancy, a history of toxoplasmosis, malaria, rubella, HIV, or exposure to other known teratogens, or a fetal trisomy. A total of 53 pregnant women meeting the inclusion criteria were recruited between April 2018 and April 2020. Enrollment was restricted to singleton pregnancies since multiple gestation constitutes a high-risk pregnancy with distinct antenatal surveillance and management, and because the INTERGROWTH-21st birthweight-percentile standard used to classify small-for-gestational age is derived from and validated for singleton pregnancies [22]. Data collection Nurses, doctors, and students involved in the care of pregnant women in the endemic area received training on project objectives, sample collection procedures, and participant communication. Quarterly refresher sessions were conducted to address questions and reinforce the training. Medical records Data on maternal age, reproductive history (parity, prior miscarriages, prior stillbirths, prior Caesarean section), medical history (obesity, smoking, alcohol use, and drug use), prenatal clinical and laboratory findings (hypertension, gestational diabetes, hemoglobin), and previous or current Leishmania skin lesions were obtained by chart review of hospital records by researchers. Anemia in pregnancy was defined as a hemoglobin concentration in blood lower than 11.0 g/dL [23]. Screening for subclinical or placental Leishmania infection in prior pregnancies was not available, as it is not part of routine antenatal care. Perinatal outcomes Newborn data obtained from medical records included estimated gestational age in weeks (as determined by the best available dating method, with ultrasound-based dating and delivery-time registration in agreement), anthropometric measurements including birthweight (g) and crown-heel length (cm). Birthweight percentile for gestational age and sex was calculated using the INTERGROWTH-21st standard [22]. Small-for-gestational age (SGA) was defined as birthweight below the 10th percentile for gestational age and sex. Placental samples At delivery, trained medical personnel collected four placental tissue samples of approximately 1 cm³ each from every participant for histological analysis and PCR testing. Placentas were sampled from four adjacent locations, two at the border and two close to the umbilical cord. Samples intended for histological analysis were stored in 1% formaldehyde (Sigma-Aldrich, USA). Samples intended for DNA extraction, PCR, or sequencing were stored in RNA Protect Tissue Reagent (Qiagen, Hilden, Germany). Buccal samples Trained medical personnel collected a buccal swab from each newborn within the first few minutes after delivery and before their first feeding. Buccal swabs were preserved in 300 μL of Cell Lysis Solution (Gentra Puregene Buccal Cell Kit, Qiagen, Hilden, Germany). All laboratory testing was performed at the Instituto Nacional de Perinatología in Mexico City. Laboratory analysis DNA extraction. Placental tissue was disrupted using a Tissue Lyser LT (Qiagen, Hilden, Germany) with steel beads (Qiagen, Hilden, Germany) for 20 min at 40 Hz. DNA extraction was then performed using a QIAamp DNA Mini Blood Kit (Qiagen, Hilden, Germany) following the manufacturer’s protocol. Buccal swabs were processed using a Gentra PureGene Buccal Cell Kit (Qiagen, Hilden, Germany) per the manufacturer’s recommendations. PCR amplification. DNA amplification for Leishmania sp. detection used the kinetoplast minicircle primers JW11 (forward, 5’-CCTATTTTACACCAACCCCCAGT-3’) and JW12 (reverse, 5’-GGGTAGGGGCGTTCTGCGAAA-3’). These primers amplify an approximately 120-bp fragment of the minicircle kDNA of L. major, which contains 10,000 copies per parasite [24]. End-point PCR used Taq PCR Master Mix (Qiagen, Germany) in a final volume of 25 μL. Cycling conditions were: initial denaturation at 95°C for 10 min; 40 cycles of denaturation at 95°C for 1 min, annealing at 58°C for 30 sec, and elongation at 72°C for 30 sec; and final extension at 72°C for 10 min (Fig 2). Representative agarose gel electrophoresis of placental samples subjected to endpoint PCR amplification. Lane 1: molecular weight marker; lane 2: reagents (no-template) control; lanes 3–16: paired border and inner placental samples; lane 17: Trypanosoma cruzi DNA as a negative amplification control; lane 18: Leishmania mexicana DNA as positive control, showing the expected 120-bp band amplified with JW11–JW12 primers. Lanes 3–4: term labor sample from a non-endemic zone, without the 120-bp band. Lanes 5–8 and 13–16: term pregnancy samples from endemic zone; the 120-bp band is present in lanes 8 and 14 (placenta border). Lanes 9–12: term pregnancy samples from two women with high-risk pregnancies who delivered at a tertiary-level hospital; the 120-bp band is visible in lanes 10 and 12. Note: This gel is representative of the PCR analysis and does not display all 18 PCR-positive participants. Densitometric analysis was performed on the 120-bp bands in lanes 8, 10, 12 and 14, and on the positive-control band in lane 18; the band-analysis report is provided in S1 File. Controls. Positive controls included Leishmania mexicana (MNYC/BZ/62/M379) and Leishmania mexicana (MHOM/MX/01/Tab3), as well as genomic DNA from Trypanosoma cruzi (ninoa mexicana), Toxoplasma gondii strain RH ATCC 50174D, and Plasmodium falciparum Welch Strain 3D7 Genomic DNA ATCC PRA-405D. Negative controls consisted of reactions without a DNA template. The integrity of the extracted DNA was verified by 1% agarose gel electrophoresis and confirmed through amplification of the human β-globin gene. Sequencing. Two sequencing protocols were followed to confirm the identity of amplified DNA. PCR-amplified bands were visualised by agarose gel electrophoresis, extracted with a QIAquick Gel Extraction Kit (Qiagen, Germany), and sent to the Instituto de Biotecnología of the Universidad Nacional Autónoma de México (UNAM) for sequencing. Secondary sequencing was also performed for the internal transcribed spacer 1 (ITS1) and 5.8S ribosomal gene regions, a validated molecular target for Leishmania species identification [25,26], at the Indiana University-Bloomington Global Environmental Health Laboratory. Bioinformatic analyses compared sequences with GenBank database records via the Basic Local Alignment Search Tool (BLAST) at the National Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov). Histology. For immunofluorescence detection of Leishmania in placental tissues, tissue sections were fixed on glass slides. Antibodies were purified from a patient with diffuse cutaneous leishmaniasis from Comalcalco, Tabasco, using a Protein G column (Sigma-Aldrich, St. Louis, MO, USA). Antibodies were labeled using the Mix-n-Stain CF 488A Antibody Labeling Kit (Sigma-Aldrich) per the manufacturer’s instructions and used at a 1:50 dilution. Counterstaining was performed using a 5 μg/mL solution of propidium iodide (Thermo Fisher Scientific, Baltics, UAB) for 3 min. Antibody purification, titration, and specificity testing against the amastigote stage are described in S1 Text and S1 Fig. To preserve antigenicity for immunofluorescence, sections destined for immunofluorescence were not stained with haematoxylin and eosin or with Giemsa. As a morphological reference for the appearance of intracellular amastigotes by Giemsa staining, a section from the footpad of a mouse experimentally infected with L. mexicana is provided (S2 Fig). Data analysis Descriptive statistics for maternal sociodemographic, reproductive, prenatal, and medical history characteristics, and infant outcomes are presented as n (%) for categorical variables, mean ± SD for normally distributed continuous variables, and median (IQR) for non-normally distributed continuous variables. Given the small and unequal group sizes, between-group comparisons used Welch’s t-test or Wilcoxon rank-sum test for continuous variables, and chi-square or Fisher’s exact test for categorical variables, as appropriate. Statistical significance was defined as p < 0.05. The prevalence ratio (PR) of small for gestational age per placental PCR positivity was estimated using a modified Poisson regression model (log link) and robust standard errors with 95% confidence intervals (95% CI) [27]. To examine the association between placental PCR status and birthweight percentile, a fractional logit regression model (quasibinomial family with logit link) was fitted and presented as odds ratios (OR) with 95% CI. Predicted mean birthweight percentiles with 95% CI were estimated from the model and displayed graphically alongside observed data. Due to the small sample size, multivariable adjustment was not performed; all regression estimates are therefore unadjusted (crude). The enrollment of 53 participants are the total number of women who met eligibility criteria and provided consent over the study period (April 2018–April 2020); no formal a priori power calculation was performed given the exploratory nature of the study. For variables with missing data, complete-case analysis was used. Hemoglobin values were available for 34 of 53 participants (64%); reasons for missingness were not recorded. Analysis of buccal PCR status was based on 52 newborns, as one swab was not received. Birthweight percentile and SGA classification were based on 52 newborns (35 PCR-negative, 17 PCR-positive), as data needed for the percentile were unavailable for one PCR-positive newborn. No additional sensitivity analyses were pre-planned given the exploratory study design. All analyses were conducted in R (version 4.6.0) through R Studio (version 2026.07.1). The source code for this manuscript, statistical analyses, and project documentation is available through the online repository: https://github.com/javimangal/leishmania-placental. The dataset supporting this study is publicly available [28]. Results Study population and PCR analysis Most (51 of 53; 96%) of the study participants delivered at the Regional Hospital of Cunduacán; the remainder gave birth at Villahermosa hospital sites (n = 2). Placental PCR was positive in 18 (34%) participants and negative in 35. The geographic distribution of PCR-positive cases across sampled localities is shown in Fig 1; positive cases were distributed across 13 out of 19 (68.4%) sampled localities. The amplification of a 120-bp fragment, which appears as a unique product when DNA is amplified from L. mexicana reference strains as well as from regional isolates, was used as the criterion for a positive result. Both the internal (near the umbilical cord) and external placental regions underwent successful PCR analysis for all 53 maternal participants. Among the 18 PCR-positive participants, positivity was detected in both placental regions in 5, exclusively in the internal region in 8, and exclusively in the external region in 5. By band intensity, the internal region was positive in 13 samples (8 intense, 5 faint) and the external region in 10 samples (5 intense, 5 faint); densitometric analysis of the representative gel is provided in S1 File. The agarose gel in Fig 2 shows a representative subset of these samples rather than all 18 PCR-positive cases; the uncropped original gel image is provided in S1 Raw Gel. Of the 52 newborn buccal swabs successfully tested for DNA integrity, 11 (21.2%) tested positive by endpoint PCR. However, only 3 cases showed matching positive results for both the buccal swab and placental samples; 8 newborns with PCR-positive buccal swabs were born from mothers with PCR-negative placentas. Confirmation of parasite presence by immunofluorescence Histological analysis was performed on eight placentas (three PCR-positive and five PCR-negative). In all participants, histological examination revealed features consistent with term placentas. In PCR-positive placentas, macrophages containing fluorescent structures resembling intact amastigotes were observed. These parasitized fluorescent macrophages (pfMØs) were detected on both the maternal and fetal sides, ranging from the syncytiotrophoblast to the chorionic villi. The pfMØs were specifically located at the margins of fetal sinusoids and on the endothelium of the basal decidua (Fig 3). Fluorescent macrophages were also identified within the characteristic reticular stroma of the basal plate and intermediate villi, extending from the syncytiotrophoblast. In all cases, fluorescence was observed inside the macrophages without surrounding inflammatory cell infiltration, suggesting the absence of an active inflammatory response. The fluorescent intracellular structures corresponded in size and morphology to Leishmania amastigotes, whose appearance by Giemsa staining is illustrated in a section from the footpad of a mouse experimentally infected with L. mexicana (S2 Fig). No pfMØs were detected in PCR-negative placentas. Immunofluorescence of a PCR-positive placenta (basal decidua). Both panels show the same field. (A) Brightfield image. (B) The same field after staining with a CF 488A–conjugated anti-Leishmania antibody (green) purified from a patient with diffuse cutaneous leishmaniasis, with propidium iodide counterstain (red). The arrow indicates a macrophage containing fluorescent intracellular amastigotes. Scale bar, 2 μm. Original magnification, × 1000. Confirmation and identification of Leishmania by sequencing Three placentas with intense bands on the PCR agarose gel were selected for band elution and sequencing. The 120-bp forward product of the first sample showed 90% homology to L. mexicana (Z11556.1); this participant was a woman aged 30–34 at 39 weeks of gestation with hypertension who delivered a newborn in the 90th weight percentile. The second sample showed 87% homology to L. amazonensis (EU370874); this participant was a woman aged 20–24 in her fourth pregnancy with a prior miscarriage who delivered at 40 weeks with a newborn also in the 90th weight percentile. A third sample showed homology to L. panamensis (M87314.1); this participant was a woman aged 25–29 with a history of miscarriage and gestational diabetes who delivered a newborn in the 95th weight percentile. All three samples presented sequence homology to a region within the minicircle of kinetoplast DNA. Separate amplification using a L. mexicana primer targeting the ITS1 and 5.8S ribosomal gene regions confirmed the presence of L. mexicana in placental samples (GenBank accession KU177477.1; 617 bp; 93–99% homology to reference strain M379). This ITS1 assay additionally identified L. mexicana (97–99% homology) in two further placental samples, distinct from the three described above. The first corresponded to a woman younger than 20 years in her second pregnancy, who had experienced a pregnancy loss at 13.1 weeks of gestation in her first pregnancy and delivered a newborn at the 10th weight percentile at 38 weeks of gestation. The second corresponded to a woman aged 20–24 years in her third pregnancy, who delivered a newborn at the 70th weight percentile at 39 weeks of gestation. Maternal and infant characteristics by Leishmania PCR status Table 1 presents the comparison of maternal and infant characteristics by placental PCR status. Most participants (69.8%) were between 20 and 35 years of age. Mean (SD) maternal age was 24.6 ± 6.6 years overall and did not differ significantly between PCR groups (p = 0.16). Most participants had delivered at least once before (11.3% had ≥ 3 prior deliveries). Average parity did not differ between groups (p = 0.27). None of the participants presented with CL lesions. None reported tobacco, alcohol, or illicit drug use during pregnancy. 10.1371/journal.pntd.0014367.t001Table 1Comparison of maternal and infant characteristics by Leishmania PCR result in placental samples.VariableTotal(n = 53)PCRnegative(n = 35)PCRpositive(n = 18)p-value Maternal age Maternal age (yrs), mean ± SD24.6 ± 6.623.7 ± 6.226.4 ± 7.10.18 a< 20 yrs, n (%)12 (22.6)10 (28.6)2 (11.1)0.32 b20–34 yrs, n (%)37 (69.8)23 (65.7)14 (77.8)≥ 35 yrs, n (%)4 (7.5)2 (5.7)2 (11.1) Reproductive history Parity, median (IQR)2.0 (1.0–3.0)2.0 (1.0–3.0)2.5 (1.0–3.0)0.36 cPrimiparas, n (%)22 (41.5)15 (42.9)7 (38.9)1.00 dMultiparas, n (%)31 (58.5)20 (57.1)11 (61.1)Prior miscarriage (multiparas), n/N (%)4/30 (13.3)1/19 (5.3)3/11 (27.3)0.13 dPrior stillbirth (multiparas), n (%)1 (3.2)1 (5.0)0 (0.0)1.00 dPrior caesarean section (multiparas), n/N (%)2/30 (6.7)1/19 (5.3)1/11 (9.1)0.26 d Maternal clinical & laboratory findings Hypertension, n (%)7 (13.2)4 (11.4)3 (16.7)0.68 dGestational diabetes, n (%)2 (3.8)1 (2.9)1 (5.6)1.00 dHaemoglobin (g/dL), mean ± SD (n = 34)12.3 ± 1.312.0 ± 1.313.0 ± 1.10.04 aAnaemia (Hb < 11.0 g/dL), n/N (%)10/34 (29.4)8/24 (33.3)2/10 (20.0)0.68 d Infant sex Male, n (%)26 (49.1)20 (57.1)6 (33.3)0.15 dFemale, n (%)27 (50.9)15 (42.9)12 (66.7) Infant PCR Buccal swabs, n positive (%), n/N11/52 (21.2)8/34 (23.5)3/18 (16.7)0.73 daWelch’s two-sample t-test. b Chi-squared test. c Wilcoxon rank-sum test. d Fisher’s exact test. Comparison of maternal and infant characteristics by Leishmania PCR result in placental samples. aWelch’s two-sample t-test. b Chi-squared test. c Wilcoxon rank-sum test. d Fisher’s exact test. Among multiparas, prior miscarriage was more common in the PCR-positive group than in the PCR-negative group (3/11 [27.3%] vs. 1/20 [5.0%]; p = 0.13), although this difference was not statistically significant. The groups did not differ significantly with respect to prior stillbirth or prior Caesarean section. The proportion of male newborns was lower in the PCR-positive group (6/18, 33.3%) than in the PCR-negative group (20/35, 57.1%), though this difference was not statistically significant (p = 0.18). Perinatal outcomes Table 2 presents the comparison of perinatal outcomes by PCR status. Gestational age and birthweight did not differ significantly between groups (p = 0.19 and p = 0.60, respectively). Crown-heel length was slightly lower in the PCR-positive group (median 50.5 vs. 52.0 cm), though this difference was not significant (p = 0.28). Five-minute Apgar scores were uniformly 9 in both groups, with no infant scoring below 7. SGA was observed in 2/17 (11.8%) of the PCR-positive group versus 2/35 (5.7%) of the PCR-negative group (p = 0.59). The crude prevalence ratio for small for gestational age of PCR-positive cases compared to PCR-negative was PR = 2.06 (95% CI: 0.32–13.39; p = 0.450). 10.1371/journal.pntd.0014367.t002Table 2Comparison of perinatal outcomes by Leishmania PCR result in placental samples.VariableTotal(n = 53)PCRnegative(n = 35)PCRpositive(n = 18)p-value Perinatal outcomes Gestational age (wks), median (IQR)39.0 (38.0–40.0)39.0 (39.0–40.0)39.0 (38.0–40.0)0.19 aBirthweight (g), median (IQR)3320.0 (3000.0–3500.0)3400.0 (3100.0–3500.0)3220.0 (2862.5–3552.5)0.60 aCrown-heel length (cm), median (IQR)51.0 (49.5–53.0)52.0 (50.0–53.0)50.5 (49.0–52.0)0.28 a Birthweight classification Weight percentile, median (IQR)55.0 (40.0–80.0)60.0 (45.0–80.0)50.0 (40.0–70.0)0.87 aSGA (< 10th percentile), n/N (%)4/52 (7.7)2/35 (5.7)2/17 (11.8)0.59 b Apgar score 5-min. Apgar score, median (IQR)9.0 (9.0–9.0)9.0 (9.0–9.0)9.0 (9.0–9.0)0.61 a5-min. Apgar score < 7, n (%)0 (0.0)0 (0.0)0 (0.0)–aWilcoxon rank-sum test; b Fisher’s exact test.Abbreviations: SGA = small-for-gestational age. Comparison of perinatal outcomes by Leishmania PCR result in placental samples. aWilcoxon rank-sum test; b Fisher’s exact test. Abbreviations: SGA = small-for-gestational age. Birthweight percentile by PCR status Placental PCR positivity was associated with a modest, non-significant reduction in birthweight percentile (Fig 4). The fractional logit model estimated lower odds of a higher birthweight percentile in PCR-positive compared to PCR-negative women (OR 0.9, 95% CI 0.45–1.78; p = 0.76). Model-predicted mean birthweight percentiles were 56.5% (95% CI 46.7–65.8) in the PCR-negative group and 53.8% (95% CI 39.9–67.1) in the PCR-positive group, corresponding to an absolute difference of 2.7 percentile points (95% CI -14.3–19.6). Birthweight percentile by placental PCR status. Points show individual observations; shaded areas correspond to the density distribution. White diamonds and bars show fractional logit predicted means with 95% confidence intervals. Discussion The present findings confirm the presence of Leishmania mexicana, a species traditionally associated with cutaneous lesions, in a relatively high proportion of human placentas from CL-endemic regions of Mexico. One-third of placentas tested positive by PCR, and parasitized macrophages were confirmed by immunofluorescence in PCR-positive placentas, without an associated inflammatory response. Congenital transmission of Leishmania is well documented for VL and is associated with adverse pregnancy outcomes, including fetal loss, low birth weight, and the subsequent development of visceral leishmaniasis in infants [29,30]. For CL, such transmission has been poorly documented. Our results, together with the recent demonstration of vertical transmission of L. donovani in a mouse model of VL [15], add to the growing body of evidence that Leishmania parasites from both visceral and cutaneous species can reach the placenta. For other hematological protozoans with congenital transmission such as Toxoplasma, Trypanosoma, and Plasmodium, adverse pregnancy effects have been predominantly associated with the first pregnancy, suggesting a protective effect of maternal immunity in subsequent pregnancies [20,31]. In contrast, in our study perinatal complications were more common in multiparas (specifically prior miscarriage), although this difference was not statistically significant. Because subclinical or congenital Leishmania infection is not screened for in routine antenatal care, the Leishmania status of these women’s previous pregnancies is unknown, and we cannot determine whether PCR-positive participants had a previously affected fetus. We propose that environmental exposure to infected sandflies in this endemic area may lead to subclinical maternal infection and subsequent parasite dissemination into the placenta during the current gestation, consistent with the lack of cutaneous lesions across all participants. Compared with the high proportion of the population harboring Leishmania parasites in this endemic zone, the prevalence of clinical disease is relatively low. Several factors may explain this discrepancy, including the low pathogenicity of circulating Leishmania strains, low parasite load, or individual host susceptibility [31]. Additionally, circulating strains in this zone have been previously reported to undergo apoptotic destruction in vitro at physiological temperature (37°C) [32]; however, within the complex in vivo environment, the parasite’s ability to survive may differ, potentially because rescue molecules may influence its persistence. Consistent with persistence in vivo, the amastigotes detected by immunofluorescence retained their characteristic oval morphology; because loss of viability in this species is accompanied by a transition from an oval to a spherical form [32], the preserved oval shape is compatible with structurally intact, potentially viable parasites rather than residual parasite debris. Whether DNA detected in tissue reflects true colonization or contamination has been central to the debate over the putative placental microbiome, where the organ’s low microbial biomass, the sensitivity of DNA-based assays, and the recovery of unexpected taxa have cast doubt on culture-independent evidence [33,34]. Our findings are less vulnerable to this ambiguity: immunofluorescence localized intact amastigotes inside placental macrophages rather than free DNA, and sequencing of the amplified product confirmed homology to Leishmania—together indicating that the PCR signal arose from whole, intracellular parasites and not from spurious or contaminating DNA. The detection of parasites by PCR does not distinguish between live and dead parasites, and this study did not include parasite cultures from placental samples, both of which are limitations of this work. A notable histological feature observed in this study, compared with infections caused by T. cruzi and T. gondii, was the absence of a host-stimulated immune response [35]. Unlike those protozoa, immune cells were not observed in the vicinity of mononuclear cells harboring Leishmania parasites, consistent with the parasite’s well-characterized ability to evade immune responses. In a mouse model of VL, IFN signal activation and cellular immune suppression have been shown to accompany placental L. donovani infection [15], further supporting the concept that Leishmania parasites may create an immunologically permissive environment within the placenta. The detection of parasite DNA in one-fifth of newborn oral cavity samples suggests either contact with amniotic fluid harboring parasites or infection via the hematological route. In a mouse model infected with L. mexicana via the footpad, the parasite disseminated to all vascularized organs studied, including the salivary glands [9], supporting the plausibility of hematogenous transmission to the newborn’s oral mucosa. Notably, 8 of the 11 buccal PCR-positive newborns were born from mothers whose placental samples tested PCR-negative. This discordance has several plausible explanations. First, placental infection may have been present but undetected: a low parasite burden together with the focal, irregular distribution of amastigotes in infected tissue means that the small fragments sampled for PCR may not have contained parasites, producing false-negative placental results despite true infection, a sampling limitation also well recognized for amastigote detection in bone-marrow aspirates in visceral leishmaniasis. Second, the newborn oral cavity may have been exposed to parasites independently of detectable placental infection, for example through contact with parasite-harboring amniotic fluid, maternal blood, or genital-tract secretions during passage through the birth canal, so that intrapartum contamination cannot be excluded. Disentangling true transplacental transmission from peripartum acquisition will require longitudinal mother–infant sampling with quantitative and more extensive placental analysis. A longitudinal follow-up of this cohort could provide valuable insights into potential long-term effects on the offspring’s immune tolerance [5]. The minor sequence variations observed among the sequenced samples suggest the existence of genetically diverse circulating strains. Future studies should analyze the protozoal microbiome of the placenta and compare the genetic sequences of parasites detected in placental tissue with those from cutaneous lesions, to identify potentially non-pathogenic strains. For T. cruzi [36] and Plasmodium [37], specific parasite strains involved in congenital transmission have been identified; it is plausible that a similar pattern exists for Leishmania. Reproductive-age women living in or travelling to tropical regions endemic for CL represent a high-risk population for adverse pregnancy outcomes and subclinical congenital transmission. In non-endemic areas, they may also serve as a potential source of Leishmania congenital transmission. The full consequences of such transmission remain unknown, as congenital CL has not been previously suspected. A key aspect to consider is the potential impact on central immune tolerance development in offspring exposed in utero, which warrants further investigation. Limitations of this study include the cross-sectional exploratory design precluding causal inferences. The sample size was small, reducing statistical power to detect differences in perinatal outcomes; expansion of the original recruitment target was rendered infeasible by the COVID-19 pandemic. PCR positivity does not confirm the presence of viable parasites as PCR detects DNA from both live and dead organisms, which may overestimate the prevalence of active infection. The absence of parasite cultures is a further limitation in this respect. Hemoglobin data were available for only 34 of 53 participants (64%), limiting the assessment of anemia as an outcome; the reasons for missing data were not recorded. The generalizability of these findings to other CL-endemic regions should be approached with caution. Sandfly vector species, circulating Leishmania strains, and host immune responses may vary substantially across geographic areas, and these results may not be representative of all endemic populations. Conclusion Leishmania DNA was detected in one-third of placentas from women living in CL-endemic zones with term pregnancies, confirming that dynamic subclinical transmission occurred below clinical expression levels. The presence of Leishmania mexicana in placental tissue was confirmed by direct immunofluorescence and sequencing. Notably, inflammatory infiltrates were not observed surrounding the mononuclear cells harboring the parasites, suggesting a clinically silent infection. Parasite DNA was also detected in the buccal mucosa of one-fifth of newborns. These findings call for increased awareness of the potential for CL-associated Leishmania species to undergo vertical transmission, with implications for maternal and neonatal health surveillance in endemic regions. Supporting information Purification and validation of the anti-Leishmania human antibody. IgG was purified from the serum of a patient with diffuse cutaneous leishmaniasis using a Protein G column and conjugated with CF 488A. Reactive fractions were identified by titration, and the working dilution and specificity were established as summarized in S1 Fig. (PDF) Validation of the anti-Leishmania human antibody used for immunofluorescence. (TIF) Giemsa-stained section from the footpad of a mouse experimentally infected with Leishmania mexicana. Representative fields at increasing magnification (×10, ×40, ×100) showing intracellular amastigotes within mononuclear cells, provided as a morphological reference for the appearance of amastigotes by Giemsa staining. (TIF) Densitometric band analysis of the agarose gel shown in Fig 2. Band-analysis report exported from AlphaView 3.4.0.0 for the gel image in Fig 2 (16-bit grayscale). Bands correspond to the 120-bp product in lanes 8, 10, 12 and 14, and to the positive-control band (Leishmania mexicana M379) in lane 18. Band intensity is not quantitative and was not associated with perinatal outcome or histological findings. (PDF) Original agarose gel image for Fig 2. Uncropped, original image of the endpoint-PCR agarose gel shown in Fig 2, captured with AlphaView software after GelRed staining. Lane identities, the molecular-weight ladder, and the 120-bp positive-control band are annotated, and wells not included in Fig 2 are marked with an X. This image is also the source of the densitometric analysis in S1 File. (PDF) 18 Jun 2026 PNTD-D-26-00898 Placentas from healthy women living in a cutaneous leishmaniasis endemic region in Mexico harbor Leishmania mexicana parasites: Potential implications for pregnancy and neonatal outcomes PLOS Neglected Tropical Diseases Dear Dr. Galindo-Sevilla, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within by Aug 16 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Andrés F. Henao-Martínez, M.D. Academic Editor PLOS Neglected Tropical Diseases Susan Madison-Antenucci Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments (if provided): Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) We ask that a manuscript source file is provided at Revision. Please upload your manuscript file as a .doc, .docx, .rtf or .tex. If you are providing a .tex file, please upload it under the item type u2018LaTeX Source Fileu2019 and leave your .pdf version as the item type u2018Manuscriptu2019. 2) We do not publish any copyright or trademark symbols that usually accompany proprietary names, eg ©, ®, or TM (e.g. next to drug or reagent names). Therefore please remove all instances of trademark/copyright symbols throughout the text, including: - ® on page: 7 - TM on page: 7. 3) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: https://journals.plos.org/plosntds/s/figures 4) Please upload a copy of Figure Fig 1-5 which you refer to in your text on pages 4, 6, 7, and 9 and 12. Or, if the figure is no longer to be included as part of the submission please remove all reference to it within the text. 5) In the online submission form, you indicated that The data underlying this study contain sensitive patient information and cannot be shared publicly to protect participant confidentiality. Deidentified data may be made available upon reasonable request to the corresponding author (norma.galindo@inper.gob.mx).. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository 2. Within the manuscript itself 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues. 6) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published. i) State the initials, alongside each funding source, of each author to receive each grant. For example: "This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM).". If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d 7) Your current Financial Disclosure states, “This study was supported by funding from the National Perinatology Institute to Dr. Galindo-Sevilla (grant #2017-3-116) and from the Indiana University President's International Research Award to Drs. Armijos and Weigel (grant #PSA-PRO-0680-2020; PIRA10302019). Dr. Berger was supported by the University of Chicago Pritzker School of Medicine Pritzker Fellowship and the American Society of Tropical Medicine and Hygiene Benjamin H. Kean Travel Fellowship. The institutional funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.” However, in your funding information on the submission form, "order of grants" mismatches. Please indicate by return email the full and correct funding information for your study and confirm the order in which funding contributions should appear. Please be sure to indicate whether the funders played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. 8) We have amended your Competing Interest statement to comply with journal style. We kindly ask that you double check the statement and let us know if anything is incorrect. 9) PLOS now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at customercare@plos.org if you have any questions. Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The methods performed are not adequate and therefore more methods and anlysis has been suggested Reviewer #2: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? YES -Is the study design appropriate to address the stated objectives? YES -Is the population clearly described and appropriate for the hypothesis being tested? YES -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? YES -Were correct statistical analysis used to support conclusions? YES -Are there concerns about ethical or regulatory requirements being met? NO ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: Results are suggested to be revised and must be reperfrmed Reviewer #2: -Does the analysis presented match the analysis plan? YES -Are the results clearly and completely presented? YES -Are the figures (Tables, Images) of sufficient quality for clarity? YES ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: Somewhat matches but should be revised as per the comments Reviewer #2: -Are the conclusions supported by the data presented? YES -Are the limitations of analysis clearly described? YES, see reviewer comments bellow -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? YES -Is public health relevance addressed? YES ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: (No Response) Reviewer #2: The font size in the caption for Figure 1 is too small. ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: Authors are suggested to work on the following comments and resubmit the manuscript. Manuscripts lacks some clarity and also proper result representation; quantification are missing. 1.Authors are suggested to add treatment options for leishmaniasis which is missing in the introduction section, recent studies have suggested potential gene KO strategies for vaccine candidates and various plant-based therapies are in use for decades. Authors are suggested to cite these publications: PMID: 40196396, PMID: 33528770, https://link.springer.com/article/10.1007/s11756-024-01656-y 2. The authors have included women with a singleton fetus pregnancy. Please provide a rationale for the same. Also the positive cases have any history of prior fetus with positive Leishmaniasis? If not, what could have been the cause of the congenital transmission this time? 3. Figure 3, appears to be a representative image from one patient sample collected across the placenta and other controls run on agarose gel. It is suggested to quantify the patient samples’ Agarose gel bands with respect (densitometric analysis), to the positive control lane 17, and possible quantification should be shown across other samples. Also how do the light and dark bands of 120bp gene in patient samples represent the disease outcome and how does that correlate with histopathology or other data? This must be discussed in the results and discussion. 4. Figure 4, A and B image legends do not match the image description. What does image 4B represent if it’s the same image, show the arrow with macrophage and intracellular parasite. Scale bar is required in the images. The parasite inside the macrophage should be quantified or the infected macrophages corresponding to Figure 4. Hand E stain of the placenta should also be incorporated. Reviewer #2: The subject of this study is extremely relevant to public health, especially in countries endemic for leishmaniasis, and is still under-researched. A few suggestions are presented below. Introduction Page 3, line 47: “Protozoan infections (malaria, toxoplasmosis, Chagas’ disease, and visceral 47 leishmaniasis)”. I suggest changing to “Diseases caused by protozoa (malaria, toxoplasmosis, Chagas, and visceral leishmaniasis)” or write the scientific names of the protozoa (not the disease) in parentheses. MATERIAL AND METHODS Page 4, line 71: The font size in the caption for Figure 1 is too small. Page 6, Figure 2: In my opinion, this figure is unnecessary; the methodology for collecting samples from the placenta and buccal mucosa of newborns is clear and already described in the paragraph (lines 123-135). RESULTS Page 9, line 209: Most (37 of 53; 96%) of the study participants….; 37 out of 53 participants is 68.9% Page 9, lines 218-221: “In five patients, both the internal and external placental regions were positive; the internal region tested positive in 13 samples (8 showing intense bands, 5 faint bands), while the external region tested positive in 10 samples (5 intense, 5 faint; Figure 3).” Figure 3 is a representative gel sample from the PCR analysis, as it shows the results of some placental samples and not all 18 positive samples. I suggest also changing the text to/or something similar to; “ “PCR positivity was observed for both the internal and external placental regions in 5 samples, exclusively for the internal region in …. samples, and solely for the external region in …. samples (Figure 3)” DISCUSSION Page 14, lines 317-320: “The detection of parasites by PCR does not distinguish between live and dead parasites, and this study did not include parasite cultures from placental samples.” Are there histological sections stained with hematoxylin-eosin? It would be interesting to show if there was inflammatory cellular infiltrate around the parasitized cells. It would also be interesting to macerate part of the infected tissues and inoculate them into culture medium or even infect laboratory animals to assess the viability/infectivity of amastigotes revealed by immunofluorescence. This could indicate that the congenital infection occurs from amastigotes present in the placenta, supporting the plausibility of hematogenous transmission to the newborn’s oral mucosa. Page 14, lines 332-336: “Notably, 8 of the 11 buccal PCR-positive newborns were born from PCR-negative placenta mothers, suggesting that the placenta is not the only potential route and that contamination at the time of delivery cannot be excluded. A longitudinal follow-up of this cohort could provide valuable insights into potential long-term effects on the offspring’s immune tolerance” Isn't it more likely that the parasite load was low or the distribution of amastigotes in the placenta was irregular, and the tissue sample collected for PCR did not contain amastigotes, even though the pregnant woman's placenta was infected? In bone marrow aspirations from patients with visceral leishmaniasis, these aspects can lead to variable results in the identification of amastigotes. What other infection mechanisms could occur, including those during childbirth? Authors have mentioned it. Discuss this further. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: NAMRATA ANAND Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 29 Jul 2026 Submitted filename: response_to_reviewers.docx 31 Aug 2026 Dear Dr. Galindo-Sevilla, We are pleased to inform you that your manuscript 'Placentas from healthy women living in a cutaneous leishmaniasis endemic region in Mexico harbor Leishmania mexicana parasites: Potential implications for pregnancy and neonatal outcomes' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Andrés F. Henao-Martínez, M.D Academic Editor PLOS Neglected Tropical Diseases Susan Madison-Antenucci Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** Dear Dr. Galindo-Sevilla, We are delighted to inform you that your manuscript, "Placentas from healthy women living in a cutaneous leishmaniasis endemic region in Mexico harbor Leishmania mexicana parasites: Potential implications for pregnancy and neonatal outcomes," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases